Types of peptides &
what the research shows

A single molecule that acts on three receptors at once — GLP-1, GIP and glucagon. A Phase 2 trial in adults with obesity (published in the New England Journal of Medicine, 2023) reported a mean weight reduction of around 24% at 48 weeks on the top dose — among the largest figures seen for any investigational agent of this class. Later-stage trials are ongoing.

A stabilised analogue of growth-hormone-releasing hormone (GHRH) and one of the few peptides here with regulatory approval. Pivotal clinical trials demonstrated roughly a 15–18% reduction in visceral (deep abdominal) fat over 26 weeks in HIV-associated lipodystrophy. It has since been studied for liver fat and cognition in ageing.

A 15-amino-acid sequence derived from a protein in gastric juice. Dozens of animal studies have reported faster healing of tendon, ligament and gut tissue, increased blood-vessel formation, and protection of tissue under stress. Robust human clinical data does not yet exist, so these findings remain preclinical.

A synthetic fragment of Thymosin Beta-4, a natural repair protein. Preclinical studies report accelerated wound closure, cell migration and soft-tissue/cardiac recovery. The parent protein has reached early human trials for wound and corneal healing.

A selective ghrelin-receptor agonist that stimulates a clean pulse of growth hormone with minimal effect on cortisol or prolactin in research models — which is why it's a common reference compound in GH-axis studies.

Combines a long-acting GHRH analogue with Ipamorelin. An early-phase human study of CJC-1295 reported growth hormone increases of several-fold and IGF-1 elevations of roughly 1.5–3× sustained for up to about six days. The blend is studied for complementary, dual-pathway stimulation.

Derived from a fragment of ACTH. Research has reported increases in BDNF (a key neurotrophic factor) and improved outcomes in models of ischaemia and oxidative stress. It is approved for clinical use in Russia for certain neurological indications.

An analogue of the immunopeptide tuftsin. Studies report anxiolytic (anti-anxiety) activity via the GABA system — in some trials comparable to standard anxiolytics but without sedation — alongside immune-modulating effects.

A tetrapeptide studied for its effect on telomerase activity and telomere length. Long-running rodent studies, particularly from Russian gerontology research, have reported effects on circadian regulation and increases in lifespan markers.

A peptide encoded within mitochondrial DNA that acts as a metabolic regulator. Preclinical work links it to improved insulin sensitivity, greater exercise capacity and adaptive responses to metabolic stress.

Also known as elamipretide, this mitochondria-targeting peptide has progressed into human trials for mitochondrial diseases and heart failure, where research has examined improvements in cellular energy production and reductions in oxidative stress.

An essential coenzyme involved in hundreds of metabolic reactions and in DNA repair. Because NAD+ levels decline substantially with age, it and its precursors are a major focus of longevity and metabolic research.

A copper-binding tripeptide found naturally in plasma. Decades of research — including controlled cosmetic studies — report improvements in skin firmness and density, collagen and elastin synthesis, wound healing and antioxidant gene expression, making it one of the best-studied peptides in skin science.

A pre-combined blend pairing the cosmetic and repair peptides described above, researched for potential complementary effects on tissue and skin remodelling.